XRAYS Quarterly Digest

XRAYS: Making Sense of Cancer Headlines
Fall Edition

XRAYS Quarterly Digest For Spring 2019

A compilation of the past quarter's reviewed articles.

FORCE's eXamining the Relevance of Articles for Young Survivors (XRAYS) program, is a reliable resource designed to help young breast cancer survivors and high-risk women navigate through breast cancer research related news and information

XRAYS study XRAYS Rating

STUDY: New targeted therapy approved for early-stage HER2-positive breast cancer

The KATHERINE trial looked at the benefit of the new drug, Kadcyla, for treating early-stage breast cancer after surgery and chemotherapy. The results of this study led to FDA approval in May 2019. (6/17/19)

XRAYS study XRAYS Rating

STUDY: A low-fat diet may decrease postmenopausal breast cancer deaths

Research reported at the 2019 annual meeting of the American Society of Clinical Oncology establishes a link between dietary fat intake and its impact on postmenopausal women’s risk of dying from breast cancer. (6/13/19)

XRAYS personal story XRAYS Rating

PERSONAL STORY: A young woman's story of genetic testing and risk-reducing mastectomy

Alejandra Campoverdi comes from a family with three generations of breast cancer. As a former White House aide and active educator in the Latina community, she has openly shared her story of genetic testing, her BRCA2 mutation and her plans for risk-reducing mastectomy at age 39. (6/6/19)

XRAYS study XRAYS Rating

STUDY: FDA approves an immunotherapy treatment for some patients with triple-negative breast cancer

The FDA approved the use of the immunotherapy drug atezolizumab (Tecentriq) in combination with the chemotherapy agent nab-paclitaxel (Abraxane) for certain patients with advanced triple-negative breast cancer. (5/26/19)

XRAYS study XRAYS Rating

STUDY: Do Vitamin B supplements alter breast cancer risk for women with BRCA mutations?

Vitamins are an essential part of our diet. Vitamin supplements are often used to improve general health. This study explores how vitamin B supplements may affect breast cancer risk in women with BRCA mutations. (5/17/19)

XRAYS study XRAYS Rating

STUDY: Smart drug shows promising results for treatment of metastatic triple-negative breast cancer

We report results of an early-stage clinical trial of a new class of drugs for metastatic triple-negative breast cancer (TNBC). IMMU-132 is a combination of two different molecules: an antibody that targets certain types of cancer and delivers a chemotherapy drug that can kill cancer cells. This study looks at whether IMMU-132 is safe and effective for treating metastatic TNBC. (4/16/19)

XRAYS guideline XRAYS Rating

GUIDELINE: Breast surgeons recommend genetic testing for all breast cancer patients


The American Society of Breast Surgeons published statement on genetic testing for hereditary breast cancer on February 10, 2019. It includes recommendations about who should be tested. Among these is the recommendation that all breast cancer patients get genetic testing, as well as women who do not have breast cancer but fit the National Comprehensive Cancer Network (NCCN) guidelines. (3/25/19)

FORCE:Facing Our Risk of Cancer Empowered